Clinical aspects of dementia with Lewy bodies

Handbook of Clinical Neurology

Volumn 89, Issue , 2008, Pages 307-311

  McKeith, Ian ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COGNITIVE DEFECT; DIFFUSE LEWY BODY DISEASE; HUMAN; REVIEW;

COGNITION DISORDERS; HUMANS; LEWY BODY DISEASE;

EID: 66049097304     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(07)01229-8     Document Type: Review

References (36)

1. Aarsland D., Mosimann U.P., and McKeith I.G. Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 17 (2004) 164-171
2. Armstrong T.P., Hansen L.A., Salmon D.P., et al. Rapidly progressive dementia in a patient with the Lewy body variant of Alzheimer's disease. Neurology 41 (1991) 1178-1180
3. Ballard C.G., Jacoby R., Del Ser T., et al. Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with Lewy bodies. Am J Psychiatry 161 (2004) 843-849
4. Barber R., Panikkar A., and McKeith I.G. Dementia with Lewy bodies: diagnosis and management. Int J Geriatr Psychiatry 16 (2001) S12-S18
5. Boeve B., Silber M., Fermen T., et al. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 16 (2001) 622-630
6. Bonelli S.B., Ransmayr G., Steffelbauer M., et al. L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia. Neurology 63 (2004) 376-378
7. Bradshaw J., Saling M., Hopwood M., et al. Fluctuating cognition in dementia with Lewy bodies and Alzheimer's disease is qualitatively distinct. J Neurol Neurosurg Psychiatry 75 (2004) 382-387
8. Burn D.J., and McKeith I.G. Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease. Mov Disord 18 (2003) S72-S79
9. Burn D.J., Rowan E.N., Minett T., et al. Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: A cross-sectional comparative study. Mov Disord 18 (2003) 884-889
10. Collerton D., Burn D., McKeith I., et al. Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia. Dement Geriatr Cogn Disord 16 (2003) 229-237
11. Collerton D., Perry E., McKeith I., et al. Why do people see things that are not there?. Brain Behav Sci 28 (2005) 737-794
12. Del-Ser T., Munoz D.G., and Hachinski V. Temporal pattern of cognitive decline and incontinence is different in Alzheimer's disease and diffuse Lewy body disease. Neurology 46 (1996) 682-686
13. Ferman T.J., Smith G.E., Boeve B.F., et al. DLB fluctuations: specific features that reliably differentiate from AD and normal aging. Neurology 62 (2004) 181-187
14. Grace J., Daniel S., Stevens T., et al. Long-term use of rivastigmine in patients with dementia with Lewy bodies: An open-label trial. Int Psychogeriatr 13 (2001) 199-205
15. Litvan I., Bhatia K.P., Burn D.J., et al. SIC Task Force Appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord 18 (2003) 467-486
16. McKeith I., Fairbairn A., Perry R., et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 305 (1992) 673-678
17. McKeith I.G., Perry R.H., Fairbairn A.F., et al. Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med 22 (1992) 911-922
18. McKeith I.G., Galasko D., Kosaka K., et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 47 (1996) 1113-1124
19. McKeith I., Del-Ser T., Spano P.F., et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356 (2000) 2031-2036
20. McKeith I., Mintzer J., Aarsland D., et al. Dementia with Lewy bodies. Lancet Neurol 3 (2004) 19-28
21. McKeith I.G., Wesnes K., Perry E., et al. Hallucinations predict attentional improvements with rivastigmine in dementia with Lewy bodies. Dement Geriatr Cogn Disord 18 (2004) 94-100
22. McKeith I., Dickson D., Emre M., et al. Dementia with Lewy Bodies: Diagnosis and Management: Third Report of the DLB Consortium. Neurology 65 (2005) 1863-1872
23. McKeith I., O'Brien J., Walker Z., et al. Sensitivity and specifity of dopamine transporter imaging with 1231-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 6 (2007) 305-313
24. Merdes A.R., Hansen L.A., Jeste D.V., et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 60 (2003) 1586-1590
25. Minett T.S.C., Thomas A., Wikinson L.M., et al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. Int J Geriatr Psychiatry 18 (2003) 988-993
26. Molloy S., McKeith I., O'Brien J.T., et al. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 76 (2005) 1200-1203
27. Mosimann U.P., Rowan E.N., Partington C.E., et al. Characteristics of visual hallucinations in Parkinson's disease dementia and dementia with Lewy bodies. Am J Geriatr Psychiatry 14 (2006) 153-160
28. O'Brien J.T., Colloby S.J., Fenwick J., et al. Dopamine transporter loss visualised with FP-CIT SPECT in Dementia with Lewy bodies. Arch Neurol 61 (2004) 919-925
29. Perry E.K., McKeith I., Thompson P., et al. Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease and Alzheimer's disease. Ann N Y Acad Sci 640 (1991) 197-202
30. Taki J., Yoshita M., Yamada M., et al. Significance of I-123-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: It can be a specific marker for Lewy body disease. Ann Nucl Med 18 (2004) 453-461
31. Thomas A.J., Burn D.J., Rowan E.N., et al. A comparison of efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry 20 (2005) 938-944
32. Walker M.P., Ayre G.A., Cummings J.L., et al. The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia. Br J Psychiatry 177 (2000) 252-256
33. Walker Z., Allen R.L., Shergill S., et al. Three years survival in patients with a clinical diagnosis of dementia with Lewy bodies. Int J Geriatr Psychiatry 15 (2000) 267-273
34. Walker Z., Costa D.C., Walker R.W.H., et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease - A comparison. Neurology 62 (2004) 1568-1572
35. Wesnes K.A., McKeith I.G., Ferrara R., et al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: A randomised placebo-controlled international study using the Cognitve Drug Research computerised assessment system. Dement Geriatr Cogn Disord 13 (2002) 183-192
36. Yoshita M., Taki J., Yamada M., et al. A clinical role for I-123 MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 71 (2001) 583-588